BGC-0222

N/A

Report date: 2022/02/16 10:25:07
NME

Base Information

Drug NameBGC-0222
Drug Alias NameBGC0222BGC-0222
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGaorui Yaoye (Beijing) Technologies Co LtdBrightgene Bio-Medical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Tianma Pharma Group Tg Bio-Pharma Co LtdGaorui Yaoye (Beijing) Technologies Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A